Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

TTNP opened at $4.03 on Thursday. The company’s 50-day simple moving average is $3.46 and its two-hundred day simple moving average is $4.49. Titan Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.